MedPath

Ziprasidone and Sertraline in PTSD

Terminated
Conditions
Post-traumatic Stress Disorder
Registration Number
NCT00248261
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Brief Summary

Serotonin re-uptake inhibitors, such as sertraline, are the medication of choice in post-traumatic stress disorder. However, it takes several weeks before they ameliorate symptoms. Therefore, we will add ziprasidone (vs. placebo) medication during the first four weeks of sertraline in order to find out if this strategy accelerates symptomatic relief.

Detailed Description

A current problem in the pharmacotherapy of PTSD is that the medication of choice, serotonin re-uptake inhibitors, take several weeks before they show considerable effects on PTSD symptoms. Addition of typical neuroleptics, such as ziprasidone, offers a potential strategy to bring about a faster symptomatic relief, because they display anxiolytic properties without the risk of dependence. Therefore, in addition to standard sertraline therapy (at least 8 weeks), we will give ziprasidone vs. placebo over the first four weeks in a double-blind randomized design.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
7
Inclusion Criteria

Clinical diagnosis of Post-Traumatic Stress Disorder

Exclusion Criteria

Lifetime psychotic disorders, current substance dependency, gravidity, lactation, tartrazine hypersensitivity, contraindication against sertraline or ziprasidone

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Post-Traumatic Diagnostic Scale (PDS)56 days
Secondary Outcome Measures
NameTimeMethod
Beck Depression Inventory (BDI)56 days

Trial Locations

Locations (1)

UKE, Dept. of Psychiatry and Psychotherapy

🇩🇪

Hamburg, Germany

© Copyright 2025. All Rights Reserved by MedPath